Emilia Alors‐Pérez

Author

Emilia Alors‐Pérez

Also Known As

Alors-Perez, Emilia, Alors-Pérez Emilia, E. Alors-Perez, E. Alors-Pérez, Emilia Alors-Perez, Emilia Alors-Pérez, Emilia Alors‐Perez, Emilia Alors‐Pérez

Publications

616

Citations

H-Index

Concepts

All Affiliations

University of Córdoba Instituto Maimónides de Investigación Biomédica de Córdoba Hospital Universitario Reina Sofía Centro de Investigación Biomédica en Red Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition

About

Emilia Alors‐Pérez is an author at University of Córdoba specializing in medicine, cell biology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	227
2	Cell Biology	3	3	118
3	Pathology	2	2	130
4	Engineering	1	1	75
5	Cancer Genetics	1	1	109

Emilia Alors‐Pérez

Publications

489

Citations

H-Index

Page 1

	Year	Citations
Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer Juan M. Jiménez‐Vacas, Vicente Herrero‐Aguayo, Antonio J. Montero‐Hidalgo, EBioMedicine UrologyGenitourinary CancerMedicineRna SplicingPathology	2020	109
Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease Mercedes del Río-Moreno, Emilia Alors‐Pérez, Sandra González‐Rubio, The Journal of Clinical Endocrinology & Metabolism	2019	100
Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer Juan M. Jiménez‐Vacas, Vicente Herrero‐Aguayo, Enrique Gómez‐Gómez, Translational research Prognostic BiomarkersSystems BiologyEngineeringMedicineBiomarker Target	2019	75
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug Emilia Alors‐Pérez, Ricardo Blázquez‐Encinas, Sonia Alcalá, Journal of Experimental & Clinical Cancer Research	2021	56
Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study Manuel D. Gahete, Mercedes del Río-Moreno, Antonio Camargo, EBioMedicine	2018	39
Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing Juan L López-Cánovas, Natalia Hermán‐Sánchez, María Trinidad Moreno-Montilla, Clinical and Translational Medicine	2022	30
Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types Mercedes del Río-Moreno, Emilia Alors‐Pérez, Patricia Borges de Souza, Translational research Somatic VariantExtracellular DomainMedicineCell BiologySomatostatin Receptor	2019	22
Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors Sergio Pedraza‐Arévalo, Emilia Alors‐Pérez, Ricardo Blázquez‐Encinas, Translational research Endocrine OncologyPancreatic CancerPathologyPancreatic Neuroendocrine TumorsMedicine	2022	21
Dietary Intervention Modulates the Expression of Splicing Machinery in Cardiovascular Patients at High Risk of Type 2 Diabetes Development: From the CORDIOPREV Study Mercedes del Río-Moreno, Raúl M. Luque, Oriol Alberto Rangel-Zúñiga, Nutrients	2020	17
Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors Aura D. Herrera‐Martínez, Manuel D. Gahete, Rafael Sánchez‐Sánchez, Clinical and Translational Gastroenterology	2018	10

Page 1